Zhejiang Hisoar Pharmaceutical Co Ltd (002099):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Zhejiang Hisoar Pharmaceutical Co Ltd (002099) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7618
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Zhejiang Hisoar Pharmaceutical Co Ltd (Hisoar) is a pharmaceutical company that offers specialty raw materials, preparations, fine chemicals, dyes and intermediates. The company offers raw drugs such as antibody, anti-virus, sugar-reducing, cardiovascular and worm-driven drugs. It produces fine chemicals such as medicine intermediates, active pharmaceutical ingredients and other customized and processed products. The company’s pharmaceutical ingredients comprise cilastatin acid, ethyl 7-chloro-2-oxoheptanoate, beta-methyl vinyl phosphate, beta-methylazetidin-2-one, panipenem, meropenem, faropenem, ertapenem, voglibose, repaglinide, metoprolol succinate, linezolid, sitagliptin phosphate, and rivaroxaban, among others. It markets its products in China and abroad. Hisoar is headquartered in Taizhou, China.

Zhejiang Hisoar Pharmaceutical Co Ltd (002099) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Zhejiang Hisoar Pharma Raises USD154.3 million in Private Placement of Shares 10
Hisoar Pharma Plans to Raise Upto USD328 Million in Private Placement of Shares 11
Debt Offering 12
Zhejiang Hisoar Completes Public Offering Of Bonds Due 2015 For US$47 Million 12
Acquisition 13
Zhejiang Hisoar Pharma Sells 16.1% Stake in Biotechnology Company for USD21.8 Million 13
Zhejiang Hisoar Pharma To Acquire 70% Stake In Suzhou Pharma Company For US$19 Million 14
Zhejiang Hisoar Pharmaceutical Co Ltd – Key Competitors 15
Zhejiang Hisoar Pharmaceutical Co Ltd – Key Employees 16
Zhejiang Hisoar Pharmaceutical Co Ltd – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Legal and Regulatory 18
Sep 12, 2018: State Food and Drug Administration: 4 batches of 41 generic drugs passed the consistency assessment 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zhejiang Hisoar Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Zhejiang Hisoar Pharma Raises USD154.3 million in Private Placement of Shares 10
Hisoar Pharma Plans to Raise Upto USD328 Million in Private Placement of Shares 11
Zhejiang Hisoar Completes Public Offering Of Bonds Due 2015 For US$47 Million 12
Zhejiang Hisoar Pharma Sells 16.1% Stake in Biotechnology Company for USD21.8 Million 13
Zhejiang Hisoar Pharma To Acquire 70% Stake In Suzhou Pharma Company For US$19 Million 14
Zhejiang Hisoar Pharmaceutical Co Ltd, Key Competitors 15
Zhejiang Hisoar Pharmaceutical Co Ltd, Key Employees 16

List of Figures
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zhejiang Hisoar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Zhejiang Hisoar Pharmaceutical Co Ltd (002099):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Rosenergoatom Concern:電力:M&Aディール及び事業提携情報
    Summary Rosenergoatom Concern (Rosenergoatom) is a subsidiary of Atomenergoprom, which is electric power generation company, mainly supplying electrical and thermal energy in Russia. The company’s major activities include design, construction, operation and decommissioning of nuclear power plants. T …
  • Yara International ASA:企業の戦略・SWOT・財務分析
    Yara International ASA - Strategy, SWOT and Corporate Finance Report Summary Yara International ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • SPX Flow Inc (FLOW):企業の財務・戦略的SWOT分析
    SPX Flow Inc (FLOW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • 01 Communique (ONE):企業の財務・戦略的SWOT分析
    Summary 01 Communique (Communique) is a technology company that develops and delivers integrated communication software and services. The company's products include I'm InTouch meeting, I'm InTouch, I'm OnCall and Communicate!. Its I'm InTouch provides a secure and easy to use PC remote access softw …
  • Amarin Corp Plc (AMRN)-製薬・医療分野:企業M&A・提携分析
    Summary Amarin Corp Plc (Amarin) is a biopharmaceutical company which develops and commercializes medicines for cardiovascular domain. The company's lead product Vascepa (icosapent ethyl) is a US FDA approved single-molecule prescription capsule used as an adjunct to diet, for the reduction of trigl …
  • Hanwha Q CELLS Co Ltd (HQCL):企業の財務・戦略的SWOT分析
    Hanwha Q CELLS Co Ltd (HQCL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Gooch & Housego PLC:企業の戦略・SWOT・財務情報
    Gooch & Housego PLC - Strategy, SWOT and Corporate Finance Report Summary Gooch & Housego PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Ei Group plc:戦略・SWOT・企業財務分析
    Ei Group plc - Strategy, SWOT and Corporate Finance Report Summary Ei Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • London Stock Exchange Group Plc:戦略・SWOT・企業財務分析
    London Stock Exchange Group Plc - Strategy, SWOT and Corporate Finance Report Summary London Stock Exchange Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • SDL plc (SDL):企業の財務・戦略的SWOT分析
    Summary SDL Plc (SDL) is a technology solution provider that offers language translation technology, services, and content management services. The company’s products include live content architect, live content create, media manager, idiom world server, campaign analytics, email manager, language w …
  • Hanesbrands Inc (HBI):企業の財務・戦略的SWOT分析
    Hanesbrands Inc (HBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Hydro-Electric Corporation:企業の戦略的SWOT分析
    Hydro-Electric Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • OpGen Inc (OPGN):製品パイプライン分析
    Summary OpGen Inc (OpGen) is a molecular diagnostics company that harnesses genomic analysis and bioinformatics to prevent the threat of antibiotic resistance and multi drug resistant organisms (MDROs). The company’s clinical laboratory services include high resolution microbial sequence analysis, s …
  • Ingram Entertainment Inc.:企業の戦略的SWOT分析
    Ingram Entertainment Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Fiskars Corp (FSKRS):企業の財務・戦略的SWOT分析
    Fiskars Corp (FSKRS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Younicos AG:電力:M&Aディール及び事業提携情報
    Summary Younicos AG (Younicos), a subsidiary of Aggreko Plc, is a provider of smart energy and grid solutions based on battery storage technology. The company offers Y-Cube plug and play energy storage solution, Y-Station building solution, and Y-Q software platform. It also provides battery packs u …
  • Sonatrach SPA:企業の戦略的SWOT分析
    Sonatrach SPA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Lincoln Pharmaceuticals Ltd (LINCOLN):製薬・医療:M&Aディール及び事業提携情報
    Summary Lincoln Pharmaceuticals Ltd (Lincoln Pharmaceuticals) manufactures, markets and exports pharmaceutical products. The company provides pharmaceuticals for cardiovascular, central nervous system, dermatology and ear nose throat disorders; gastrointestinal and genitourinary infections; hematolo …
  • AviChina Industry & Technology Co., Ltd. (2357):企業の財務・戦略的SWOT分析
    AviChina Industry & Technology Co., Ltd. (2357) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • Fitbit Inc.:戦略・SWOT・企業財務分析
    Fitbit Inc. - Strategy, SWOT and Corporate Finance Report Summary Fitbit Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆